Meeting
2021 ASCO Quality Care Symposium
Prostate-specific antigen response among Black and non-Black patients with advanced prostate cancer treated with apalutamide in a urology setting.
Authors
Michael Durkin
Janssen Scientific Affairs, LLC, Titusville, NJ
Michael Durkin, Dominic Pilon, Carmine Rossi, Ibrahim Khilfeh, Frederic Kinkead, Caterina Wu, Lorie Ellis, Patrick Lefebvre
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cost, Value, and Policy; Health Equity and Disparities; Patient Experience
Track
Cost, Value, and Policy,Technology and Innovation in Quality of Care,Health Care Access, Equity, and Disparities,Patient Experience,Quality, Safety, and Implementation Science
Sub Track
Health Disparities
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 124)
DOI
10.1200/JCO.2020.39.28_suppl.124
Abstract #
124
Poster Bd #
D18
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices.
First Author: Gordon Andrew Brown
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world comparison of prostate-specific antigen (PSA) response in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) or enzalutamide (ENZ).
First Author: Benjamin H. Lowentritt
Poster
2022 ASCO Genitourinary Cancers Symposium
Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.
First Author: Eric Jay Small
Poster
2020 ASCO Virtual Scientific Program
Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies.
First Author: Kim N. Chi